An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper.
Steger Jennifer S, Durai Indira, Odayappan Annamalai, Raman Ramalakshmi, Sruthi Talla, Song Allisa J, Puthuran George, Venkatesh Rengaraj, Colantuoni Elizabeth, Robin Alan L
AI Summary
Timolol microdrops effectively reduced eye pressure in glaucoma patients, similar to conventional drops, with slightly less impact on heart rate, suggesting a more efficient and safer delivery.
Abstract
Purpose
To examine if 12.5 μl timolol maleate 0.5% microdrops dispensed with the Nanodropper Adaptor provide noninferior intraocular pressure (IOP) reduction compared with conventional 28 μl drops in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT).
Design
Prospective, noninferiority, parallel, multicenter, single-masked, active-controlled, randomized trial.
Participants
Treatment-naïve subjects who were recently diagnosed with OAG and OHT at the Aravind Eye Care System.
Methods
Both eyes of subjects received 1 commercially available drop or both eyes of subjects received 1 microdrop of timolol maleate 0.5%. We measured IOP, resting heart rate (HR), and blood pressure (BP) at baseline and 1, 2, 5, and 8 hours after timolol administration.
Main outcome measures
The IOP was the primary outcome measure. Secondary outcomes were resting HR, systolic BP (sBP), and diastolic BP (dBP).
Results
Adaptor-mediated microdrops and conventional drops of timolol significantly decreased IOP compared with baseline at all timepoints. Noninferiority was established at 3 of 4 timepoints. Heart rate decreases with Nanodropper were approximately 3 beats per minute (bpm) less than with conventional drops.
Conclusions
Timolol microdrops appear to be as effective in ocular hypotensive action as conventional drops with a slightly attenuated effect on resting HR and BP.
Financial disclosure(s): Proprietary or commercial disclosure may be found after the references.
MeSH Terms
Shields Classification
Key Concepts4
Timolol maleate 0.5% microdrops (12.5 μl) dispensed with the Nanodropper Adaptor significantly decreased intraocular pressure (IOP) compared with baseline in treatment-naïve subjects recently diagnosed with open-angle glaucoma (OAG) and ocular hypertension (OHT).
Conventional 28 μl drops of timolol maleate 0.5% significantly decreased intraocular pressure (IOP) compared with baseline in treatment-naïve subjects recently diagnosed with open-angle glaucoma (OAG) and ocular hypertension (OHT).
Noninferiority of timolol maleate 0.5% microdrops (12.5 μl) dispensed with the Nanodropper Adaptor compared with conventional 28 μl drops was established at 3 of 4 timepoints for intraocular pressure (IOP) reduction in treatment-naïve subjects recently diagnosed with open-angle glaucoma (OAG) and ocular hypertension (OHT).
Heart rate decreases with timolol maleate 0.5% microdrops dispensed with the Nanodropper Adaptor were approximately 3 beats per minute (bpm) less than with conventional 28 μl drops in treatment-naïve subjects recently diagnosed with open-angle glaucoma (OAG) and ocular hypertension (OHT).
Related Articles5
Safety and Efficacy of Omidenepag Isopropyl for Elevated Intraocular Pressure: A Systematic Review and Meta-Analysis.
Systematic ReviewShort-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study.
Observational StudyPhase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty.
Randomized Controlled TrialOcular effects of Rho kinase (ROCK) inhibition: a systematic review.
Systematic ReviewA phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension.
Randomized Controlled TrialIs this article assigned to the wrong chapter(s)? Let us know.